在一名合并感染HIV-1的患者中，NS5A耐药导致索磷布韦/维帕他韦与利巴韦林联合进行24周治疗未能治愈丙型肝炎基因1a型感染。
NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.
作者信息
Sevastianova Ksenia, Dean Jonathan, Bannan Ciaran, Coghlan Miriam, Farrell Gillian, Murray Catherine, De Gascun Cillian F, Bergin Colm
机构信息
Department of Genitourinary Medicine and Infectious Diseases, St. James's Hospital, Dublin, Ireland.
National Virus Reference Laboratory, University College Dublin, Dublin, Ireland.
出版信息
J Clin Virol. 2016 Sep;82:66-69. doi: 10.1016/j.jcv.2016.06.012. Epub 2016 Jun 23.
Herein we report a previously undescribed case of treatment-emergent non-structural protein 5A (NS5A) resistance mutations, Q30H and Y93C, leading to a failure of 24-week course of sofosbuvir/ledipasvir+ribavirin therapy for the treatment of hepatitis C virus (HCV) genotype 1a in interferon-experienced, human immunodeficiency virus type 1 (HIV-1) co-infected patient with cirrhosis.
在此，我们报告了一例先前未描述的治疗中出现的非结构蛋白5A（NS5A）耐药突变病例，即Q30H和Y93C，这导致一名有干扰素治疗史、合并感染人类免疫缺陷病毒1型（HIV-1）且患有肝硬化的丙型肝炎病毒（HCV）1a型患者接受的索磷布韦/维帕他韦+利巴韦林24周疗程治疗失败。
Zotero 插件